Vaccines have been used for centuries to immunize individuals against pathogenic organisms with the goal of preventing the associated disease. Vaccines are biological products that contain antigens capable of inducing a specific and active acquired immune response in the body. Antigens present in vaccines are processed by specialized cells in the body's immune system, resulting in the development of blood proteins known as antibodies (i.e., humoral immunity) or specialized lymphocytes (i.e., cell-mediated immunity) or both. Therefore immune responses may be antibody mediated, cell mediated, or both. Thus, antigens are critical for vaccine function and generally consist of a portion of the pathogenic organism, or an attenuated form of the whole microorganism. In the case of DNA-based vaccines (currently under development), the vaccine would contain nucleotide sequences (genetic material) that encode microbial antigens.
Examples of types of licensed vaccines appear in Appendix 1. A current list of vaccines licensed in the United States is posted at www.fda.gov/cber/.
Vaccines can be of various types, depending on their design and processes involved in their manufacture. Vaccines for human use may contain whole killed or attenuated organisms (e.g., bacteria or viruses) or contain antigens derived from portions of a pathogen, either by partitioning and purification or derived using recombinant technology (Table 1). Some polysaccharide vaccines are conjugated to a carrier in order to enhance their immune response.
Table 1. Bacterial and Viral Vaccines
Live attenuated whole cell or virusa
Whole cell or virusc
Recombinant proteinsd
Modified toxins
a   Live attenuated bacterial or viral vaccines are weakened (attenuated) forms of a pathogen. They contain antigens that are similar to disease-causing microbes. They may be derived from the pathogen itself, or from a different organism that contains antigens that cross-react with the virulent microbe (e.g., vaccinia and variola).
b   Inactivated bacterial and viral vaccines are produced by growing cells of disease-causing bacteria or viruses in cell substrates and subsequently inactivating them to prevent replication in the recipient.
c   Inactivated/killed whole-cell or virus vaccines consist of the entire microorganisms after they have been inactivated. These preparations may or may not be partially or completely purified.
d   Recombinant protein viral and bacterial vaccines are derived from host cells that have been transformed with expression vectors that carry genes that encode antigenic material from infectious agents. The expression cells are grown in bioreactors to produce the recombinant antigenic material.
e   Subunit vaccines are extracts from inactivated/killed viruses or bacteria. Subunit-type vaccines generally undergo some degree of purification.
In addition to antigen(s), vaccines may contain several other components, such as adjuvants that enhance the immune response to the vaccine antigen, preservatives to prevent bacterial or fungal contamination of multiple-dose vials, or other excipients needed for pharmaceutical manufacturing or vaccine stabilization. Residual components from the manufacturing process also may be present in vaccine preparations. Examples of these categories are listed in Table 2.
Table 2. Vaccine Components
Whole organisms
Recombinant proteins
Aluminum salts
Antimicrobial preservatives
Benzethonium chloride
Amino acids
Manufacturing residuals
Cell-derived residuals
Materials of animal origin
Antibiotic residuals
Inactivating chemical agents
Different vaccine antigens are often combined in one final formulation in order to elicit immunity against multiple diseases and to reduce the number of separate administrations needed to achieve immunity to the various vaccine antigens.
Despite the multiple forms vaccines may take, several common features characterize the manufacture and testing of vaccines. This chapter focuses on commonalities throughout the manufacturing process, from raw material qualifications to final release tests.
Regulations and Standards
Vaccines are regulated by FDA as biological products. The general requirements are listed in national laws and international guidances. For the U.S., national requirements are codified in 21 CFR, the 200 and 600 sections, with additional recommendations available in FDA Points to Consider and Guidance documents (www.fda.gov). International guidances are available from the International Conference on Harmonization (ICH) (www.ich.org; see Appendix 2) and the World Health Organization. New methodologies are continually being developed and validated and will be included in USP as they become available. Reference standards are available from USP and FDA.

When considering the overall plan for manufacturing a vaccine, manufacturers need to consider the following factors:
  • Physical facilities;
  • Raw materials and process aids;
  • Actual manufacturing process, including
    1. initial process (production of virus/bacteria and recombinant materials);
    2. downstream processes (purification or chemical modification, if applicable);
  • Antigen modifications such as conjugation or toxoiding;
  • Storage of process intermediates and final bulk;
  • In-process and final product testing regimens and control schemes;
  • Addition of adjuvants, if applicable;
  • Formulation and filling;
  • Container–closure system; and
  • Stability program that supports the dating period of the product.
Quality systems are needed to support the following manufacturing process development: specifications for raw materials, process intermediates, and final product; change control; and failure investigations and complaints. All of these elements are important in the life cycle of the vaccine product.
The overall goal of a comprehensive manufacturing program is to consistently produce a vaccine that is safe and effective. Concurrently with clinical development of the vaccine, the manufacturing process is refined and the process and testing methods are validated for consistency. This includes systems to control changes to the process or inputs. Manufacturers should expect that changes will be required during the vaccine's manufacturing life cycle, and manufacturers necessarily will use data from development and routine manufacturing to assess the process as well as proposed changes. The manufacturers should adopt systems that continually evaluate all aspects of manufacturing to identify unanticipated changes in vaccine quality and to assess them as quickly as possible.
Manufacturing Facilities and Systems
Manufacturers should have a general layout of manufacturing facilities, including diagrams that show the following: flow of raw materials and process inputs; movement of product, intermediates, waste streams, and personnel; and air flows and pressurization levels. These diagrams assist in minimizing the risk of potential product contamination from various sources. These sources can include cross-contamination from other products, contamination from different batches of the same product, and extraneous contamination from microorganisms and personnel. Evaluation of the flow diagrams can assist with strategies for development of engineering controls, personnel procedures, and monitoring systems to enable compliance with Good Manufacturing Practices (GMPs). Analysis of potential risks may also provide insights about what information should be recorded in batch documentation to facilitate consistent manufacture and also to facilitate failure investigations. Together, physical facilities, procedures, personnel, training, and quality systems make up the GMP environment in which a vaccine will be produced.
Manufacturing Process
The manufacturing process includes process inputs such as raw materials and processing aids and unit operations comprising both the initial and downstream processing steps. A process flow map for the manufacturing process is useful and assists in validation of the manufacturing process. This map shows all unit operations, the inputs to each operation, and the outputs to subsequent manufacturing steps. Analytical testing done at relevant steps and the specifications required to proceed to the next stage of processing may be added to the map. A process map also supports a processing space to facilitate a rugged process, i.e., one based on suitable characterization studies to establish boundaries within which manufacturing can occur to promote unchanged safety and efficacy outcomes.
The process flow map should include all steps from making the seed/cell bank (described below) to formulation and filling of the final product. The validation strategy should include the steps that require validation, along with identification of the process space, associated critical process parameters (CPP), and critical quality attributes (CQA). The critical process parameters are those that directly affect core quality attributes needed to successfully manufacture a batch of product. Some manufacturers identify other processing parameters that are important for processing but do not affect critical quality attributes. These important but noncritical factors help identify the process development space, can contribute to the development of a rugged process, or can be useful when the company assesses processing deviations. The concepts of quality by design and exploration of the process space are relatively new to the biologics/vaccine industry but are becoming considerations for the overall development-planning process.
Manufacturing Surveillance
Manufacturing surveillance is the continual observation of how the process and the resulting product are performing. This section is not exhaustive; rather, the points raised here outline the types of considerations recommended for a manufacturer during development of a vaccine. Manufacturing surveillance includes the following:
  • Periodic review of the performance of the manufacturing process;
  • Analytical assays;
  • Stability programs;
  • Product complaints;
  • Adverse event reports;
  • Product failure investigations;
  • Atypical or deviation events.
Taken as a whole, these activities allow a manufacturer to assess the state of the process and product and to evaluate which, if any, operations need to be modified. These same systems also provide a surveillance matrix to evaluate changes. In any of these programs it is also valuable to develop additional characterization assays that are not used for process intermediate or product release purposes but may be used for further evaluation when additional information is needed or desired. These additional assays for characterization are often based on different underlying analytical procedures to provide different ways to evaluate materials.
Routine surveillance processes are increasingly implemented to attempt to detect changes in processes before any critical quality attributes are adversely affected. Not all vaccine processes can be characterized to the same extent or level (e.g., a live virus vaccine vs. a recombinant protein vaccine), and statistical tools are often used to determine alert or action levels in surveillance programs. Exceeding these levels requires the manufacturer to evaluate the situation but does not necessarily signal product failure.
GMP manufacturing entails facility design, process development, quality systems, and manufacturing surveillance. Together these systems help the manufacturer to control the production of a vaccine. As noted, many types of vaccine are marketed, and each has its unique features and therefore requires different plans for each of the steps mentioned in this section.

Seed lots are the stocks of specific strains of bacteria, viruses, or biotechnology-engineered cells used to express vaccine antigens. All seed lots should be documented in terms of their isolation, derivation (or construction, in the case of recombinant vector or engineered cells), and passage history. The purpose of a seed-lot system, which typically includes master and working stock seeds, and associated master and working cell banks, is to help ensure the consistency of vaccine manufacturing. The use of master and working seed lots provides a method to limit the replication of the seed and to minimize the possibility of genetic variation.
A master seed lot is a physically homogeneous preparation derived from an original seed processed at one time and passaged for a limited number of times. The master seed lot is characterized for its biological, biochemical and genetic characteristics, and to ensure its purity, its freedom from adventitious agents, and its clinical ability to produce an effective vaccine.
Cultures from the working seed lot should have the same characteristics as the master seed lot from which they are derived. For influenza vaccines, which may be reformulated with new virus antigens each year, certified seed lots can be obtained from national regulatory agencies.
A working seed lot is derived from the master seed within a limited number of passages. The working seed is tested to ensure its purity, freedom from adventitious agents, and biochemical properties. The working seed is used for production of vaccine without intervening passages.
Bacterial Vaccine Seed Lot System
In the bacterial seed lot system, a master seed is subcultured to produce a working seed one passage beyond the master seed. An aliquot of the working seed is then expanded to produce a vaccine lot. The strain(s) used for the master seed lots are identified by historical records that include information about their origin. Information about the bacterial seed lot system should include source, passage history, and raw materials to which it was exposed, with specific emphasis on raw materials of ruminant origin. Seeds should be stored at an appropriate temperature in more than one location within a facility or at a distant site in order to decrease catastrophic risk.
Identity tests may include inoculation onto suitable biochemical media, Gram stains, genotype, and serological identification with suitable specific antisera. Special tests may be added, for example, to show culture viability but also lack of virulence.
Purity of the bacterial strains used for seed lots is verified by methods of suitable sensitivity to ensure that no adventitious agents are present. These purity tests often are performed in the presence of the seed under conditions where growth is inhibited by the presence or the absence of specific nutrients. Streaking can also be used to show that the cultured seed is a pure culture.
Viral Vaccine Seed Lot System
The derivation and passage history of viral seeds should be recorded in detail. Any manipulation of the viral phenotype (e.g., cold adaptation, development of temperature sensitivity, or attenuation of virulence) or intentional genetic manipulations (e.g., reassortment or recombination) should be documented.
These viral seeds are commonly differentiated into a master viral seed and working viral seeds or working viral stock. Viral seeds should be stored at cryogenic temperatures to promote stability and in more than one location within a facility or at a distant site to decrease catastrophic risk. Manufacturers should assess the following characteristics of the viral seed stock:
  • Growth characteristics on the intended production cell substrate,
  • Tissue tropism;
  • Genetic markers;
  • Identity (for recombinant vectors);
  • Viability during storage,
  • Genetic stability through production;
  • Attenuation properties;
  • Purity;
  • Absence of adventitious agents. If attenuation or derivation is achieved by passage through different species, the viral seed should be assessed for absence of adventitious agents common to those species.
The master viral seed should be extensively characterized to demonstrate the stability of genotype and phenotype for a number of passages beyond the level used in production. Generally, during assessment of genetic stability, a master seed undergoes a minimum of five passes beyond the passage that will produce the final vaccine.
Tests should be performed for identity (e.g., sequencing the entire virus or a portion of it), adventitious agents, viral phenotype, genetic stability, and, if applicable, agents that might be present in the seed as a result of its passage history. Viral phenotype can be assessed further for tissue tropism, attenuation properties, and temperature sensitivity. Not all of these tests may be necessary for every viral seed strain.
In some cases the viral seeds may have a broad host range and therefore may require neutralization of the vaccine virus before they are tested for adventitious agent(s). If possible, testing for adventitious agents should be done without neutralization in order to avoid an antiserum that may inadvertently neutralize an adventitious agent present in the seed. Sometimes it is not possible to effectively neutralize a viral seed, and in such cases alternative strategies can be used. For example, the test can be performed in a cell substrate that does not permit replication by the vaccine virus. However, such a substitution of the substrate cell may compromise the test's sensitivity for detection of other adventitious agents. Therefore, the tests may be supplemented with use of polymerase chain reaction (PCR) assays.
Assessment of neurovirulence may be appropriate if the virus is known to be neurotropic. Manufacturers should consult with regulators about appropriate animal models, methods, and scoring systems for this assessment before they initiate such studies. For viruses that are neurovirulent or may revert to neurovirulence (e.g., polioviruses), it may be necessary to assess neurovirulence beyond the master seed.
If the master viral seed is well characterized, the working viral seed may not require extensive characterization. For example, it may not be necessary to repeat testing for all the relevant viruses from the derivation history.
Systems for Biotechnology-Engineered Vaccines
For a vaccine produced via a biotechnology-engineered cell-expression system, a master seed lot or a master cell bank will be established during product development. The seed lot or cell banks should be homogenous, which is often accomplished by limiting dilutions. The seed lot or cell bank system should be characterized in a manner analogous to that used for the cell substrate discussed in the next section, and additional tests can be used to demonstrate the genetic stability of the expression system.

A medium is the material in which an organism is grown and amplified in quantity to produce mass material for vaccine production. Its composition is diverse and depends on the cell types that the medium supports, ranging from well-defined chemical media to chemically undefined media that contain natural components such as sera from animal origin (see Bovine Serum 1024). Culture media should be suitable for their intended purpose and should be free from adventitious agents and known undesirable components such as toxins, allergens, and similar compounds. If undefined ingredients are necessary, the amount should be kept below levels that are demonstrated to be safe for the final product.
Fermentation Media for Bacterial Growth
The nutrients consist of materials like proteins, sugars, inorganic trace elements, amino acids, and vitamins needed for bacterial growth. The protein component may be as simple as free casein (milk protein), or it can be as complex as extracts from bacterial, plant, or animal sources. Any fermentation nutrients of animal origin are sourced carefully and tested for adventitious agents. The composition of a medium is often customized to optimize product quality attributes. Medium components that are known to cause allergic reactions should be avoided.
Media for Cell Culture for Viral Vaccines
The types and composition of media used for isolation and all subsequent culture of components of viral vaccines need to be recorded in detail. Chemically defined media without materials of animal origin are preferred. The medium should be tested for sterility and suitability for the cells used in product production. If materials of animal origin are used, they are assessed for freedom from adventitious agents. If human albumin is used in a U.S.-licensed vaccine, it must be licensed by FDA. The final product should be within specified limits of residual medium components such as serum, antibiotics, selection agents or reagents added for growth enhancement.
Media for Biotechnology-Engineered Cells
The requirement for media used for the fermentation and propagation of biotechnology-engineered cells is the same as that noted above for bacterial fermentation and cell culture growth.

The propagation and harvest phases follow the manufacturing process from the initiation of cell growth in the working cell bank to the separation of the crude drug substance. In addition, in these manufacturing process steps, raw materials, media, and solutions should be qualified for their intended use. Batch numbers should be clearly assigned as needed, and the relationship between component harvests and batches of individual drug substances should be recorded clearly.
Propagation and Harvest for Bacterial Vaccines
Propagation of bacteria for bacterial vaccines is performed under specified conditions for the inoculum preparation and the fermentation phases. In-process monitoring and testing should be conducted for quality assurance. All controls and testing performed after production (e.g., purity, viability, antigen yield, and phenotypic identity) should be documented. The first step of drug-substance recovery is harvesting from the bioreactor. A variety of equipment is available, and the process equipment used depends on the nature of the process. Procedures should be established to ensure containment and prevention of contamination during harvesting and to monitor bioburden (including acceptance criteria) or sterility. The storage conditions and the stability time limit for the harvest material should be described. For most bacterial vaccines, an inactivation step is necessary. Personnel involved in bacterial inactivation should consider the following: how cell culture purity is verified after inactivation, whether culture purity should be defined before inactivation, choice of the inactivation agent, and validation of the procedure(s).
Propagation and Harvest for Viral Vaccines
The manufacturing of viral vaccines using eukaryotic cell culture includes a two-phase production process. The first is the expansion of the cell cultures used as a substrate for viral replication. The second phase includes the initial virus infection and subsequent replication and virus production.
Cell Substrate Growth Phase— The cell substrate expansion process for viral production is the phase designed to prepare the cells in a physiological state appropriate to sustain virus growth. Cell substrates often require complex animal-derived supplements such as serum. The source and testing requirements of bovine serum are subject to regulatory requirements (see Bovine Serum 1024).
Virus Production Phase— Relatively few cell types have been used as substrates in U.S.-licensed viral vaccines, but these include primary cells (e.g., certain cells derived from monkey, chick, or mouse tissue), diploid cell lines (e.g., WI-38, MRC-5, or FRhL-2), and continuous cell lines (e.g., Vero). Vaccine manufacturers have optimized nutrient requirements, growth factors, and serum concentration to support robust growth and strong virus productivity for these cell lines.

The objective of the purification steps is to remove as much as possible of the impurities in the initial harvest and to maximize the purity of the final vaccine product. Process residuals may consist of materials from the culture medium and/or cellular components. Purification procedures should be optimized and validated. When applicable, viral clearance steps (viral removal or inactivation) should be included and validated using relevant model viruses. Special considerations are observed depending on the types of vaccines and production system used, as discussed below.
Bacterial Fermentation
Bacterial fermentations are typically highly productive and yield large amounts of biomass. For bacterial subunit products or recombinant components expressed by bacteria, fermentation can produce very high concentrations of the desired active ingredient. Manufacturers should initiate culture purity testing before further processing.
Live Bacterial Vaccines— Live bacterial vaccines such as Bacillus Calmette-Guérin (BCG) and Salmonella typhi Ty21a are relatively fragile as pharmaceutical products and therefore tolerate only fairly gentle purification approaches. If osmotic and shear forces are constrained, then the integrity of the bacteria usually can be maintained.
Inactivated Bacterial Vaccines— At present no inactivated whole-cell bacterial vaccines are licensed for use in the U.S.
Purified Bacterial Antigens— Purification of bacterial components (e.g., proteins, toxins, and polysaccharides) generally requires cell disruption. More selective purification methods can be used to remove culture media and bacterial impurities and to achieve high purity of the target bacterial component.
Biotechnology-Engineered Cells
Of special concern in the purification of recombinant-derived vaccine components is the issue of residual host cell components that could produce an adverse immunogenic response in patients. This response could be exacerbated by the presence of vaccine adjuvants.
Recombinant Virus-Like Particles (VLP)— Formation of VLPs can coincidentally result in incorporation of host cell components (e.g., DNA) into the quaternary structure of the molecular assembly, resulting in a class of impurities that has a tight association with the active pharmaceutical ingredient. As a result, modern approaches to VLP production in some cases include a disassembly step that dissociates impurities from the viral proteins. This procedure is followed by a reassembly step that reforms the VLPs in the absence of the host components. Liquid-phase extractions and chromatographic procedures can be used to provide high-purity components for use in vaccine products with no substantial risk of carrying over significant residual host components.
Viral Vaccines Derived from Cell Culture
Viral Vaccines Derived from Continuous Cell Lines— If a continuous cell line (e.g., Vero) is used for vaccine production, a validated filtration step is necessary to separate virus from intact cells. The quantity and size of any residual host cell DNA also should be determined (see general information chapter Nucleic Acid-Based Techniques—Approaches for Detecting Trace Nucleic Acids (Residual DNA Testing) 1130). Currently, 10 ng of host cell DNA is permitted per dose of a parenterally administered vaccine, and regulatory agencies continue to consider on a case-by-case basis the level of risk posed by host cell DNA for vaccines that are administered by other routes (e.g., nasal or oral). Multiple purification methods to reduce the size and amount of residual host-cell DNA present in the vaccine are desirable and include steps such as treatment with DNAse, diafiltration, ultrafiltration, and column chromatography.
Viral Vaccines Derived from Human Diploid Cell Culture— FDA has licensed several vaccines made using human diploid cells. The two most commonly used diploid cell lines are MRC-5 and WI-38, both of which are derived from human embryonic cells and have the normal diploid number of human chromosomes. They are widely used to manufacture vaccines because they have been shown to have no tumorigenic or oncogenic potential and have been shown to be susceptible to a wide range of human viruses. However, unlike continuous cell lines that can be passaged indefinitely, human diploid cell lines are capable of attaining only a certain number of population doublings, after which they experience a rapid decline in their ability to proliferate. This issue is managed by freezing multiple aliquots of master and working cell banks.
Viral Vaccines Derived from Primary Cell Culture— Like diploid cells, primary cells normally are not tumorigenic or oncogenic. However, when primary cells are used to manufacture live vaccines, the donor animals from which the primary cells are obtained are extensively tested for a variety of pathogens before being used. For example, chicken flocks used to prepare chicken embryo kidney cells undergo extensive serological testing for adventitious agents before the flock can be used to prepare the cells. Some of these tests are described in the Code of Federal Regulations (CFR, see the sections listed in Appendix 2) and the USP general information chapter Virology Test Methods 1237.
Viral Vaccines Derived from Chicken Eggs
The embryonated chicken egg is a highly productive growth substrate for certain viruses, such as those used to make vaccines for yellow fever and several influenza vaccines. In the case of influenza vaccines, vaccine virus is harvested from egg allantoic fluid. In the case of yellow fever vaccine, the vaccine virus is harvested from embryo tissues. Therefore, residual egg or embryo components are special considerations in vaccine purification.
Egg-based vaccine production, like all biomass expansions, requires care and quality control of the virus seed lots and egg substrates to avoid contamination with other organisms.
Live Attenuated Virus Vaccines— Viruses for live vaccines (e.g., yellow fever or live influenza) are produced using Specific Pathogen-Free (SPF) eggs. These eggs are produced by chicken flocks that are regularly screened for avian pathogens (e.g., avian leukosis virus) and are maintained using appropriate animal husbandry practices. To preserve the infectivity and antigenic integrity of the vaccine viruses while removing egg-derived components, relatively simple, mild methods (e.g., zonal sucrose gradient centrifugation and diafiltration) are used for vaccine virus concentration, purification, and buffer exchange.
Inactivated Whole Virus Vaccines— Viruses for inactivated vaccines can be produced using non-SPF eggs because of required chemical inactivation steps in the manufacturing process. Because the vaccine virus needs to be retained intact while removing egg-derived components and inactivating chemicals, relatively mild purification and concentration methods (e.g., zonal sucrose gradient centrifugation) are used. If chemical agents are used in the process, they should be minimized in the final product to below prespecified levels.
Split Virus and Purified Subunit Vaccines— Viruses for split virus and purified subunit influenza vaccines are produced in non-SPF embryonated eggs. Inactivation and purification of vaccine viruses are achieved by chemical treatment (e.g., formaldehyde or -propiolactone) and zonal sucrose gradient centrifugation, respectively. Split virus vaccines are prepared by disruption of vaccine virus particles using a detergent (e.g., sodium deoxycholate) that preserves antigenic integrity.

Intermediates are defined here as the unformulated active (immunogenic) drug substances that are processed before final formulation and can be stored for long periods of time before further processing. These intermediates can be stored and should be included in a formal stability program. Examples of intermediates include bulk polysaccharides, purified recombinant proteins (concentrates), and conjugates.
Production of Intermediates
Intermediates are manufactured from starting materials by one or a combination of different processes (e.g., fermentation, cultivation, isolation, or synthesis). Subsequent steps of the procedure involve preparation, characterization, and purification, eventually resulting in the drug substance. Quality systems documents are adopted for production and all applicable information should be recorded in a controlled document (i.e., a batch record). When applicable, stability studies and release tests should be performed before proceeding to the next steps (see below).
Tests for Intermediates
The quality attributes of the intermediate are commonly tested in conjunction with further processing. Characterization beyond release testing should be considered. Characterization methods can use appropriately qualified procedures. Some tests are routinely performed before the intermediates are converted to the final bulk, depending on individual vaccines.
If intermediates need to be stored and/or subsequently shipped to a different location for further processing, the stability of these materials should be demonstrated. Stability tests can be a combination of both physicochemical analysis and biological assays.

Final bulk is the bulk drug product that contains the drug substance(s), excipients, and other ingredients at desired concentrations and is ready for filling into individual containers.
Production of Final Bulk
Appropriately controlled amounts of all ingredients are blended to uniformity to produce the final bulk. The processing may include one or more steps such as buffer exchange and addition of diluents, bulking agent, stabilizing excipients, adjuvants, and preservatives. Final bulk may be prepared aseptically or processing may include a sterilization step.
Tests for Final Bulk
The quality attributes of the final bulk should be tested. Appropriate testing should be performed with respect to identity, purity, potency, sterility (see Sterility Tests 71), and antimicrobial effectiveness (see Antimicrobial Effectiveness Testing 51). Tests demonstrating safety, if applicable, are performed. The list includes, for example, tests for the absence of adventitious agents, mycoplasma, and other microorganisms.
Testing is required for specific process-related and product-related impurities, depending on the vaccines being manufactured. In addition, tests are required for the bulking agent, stabilizing excipients, adjuvants, and/or preservatives, if used. All the testing should be done according to respective standard operating procedures (SOPs), and all tests should have specifications (or provisional specifications, where applicable).
Stability Test for Final Bulk
If final bulks are stored and/or subsequently shipped to a different location for further processing, the stability of these materials should be demonstrated. Stability tests can be a combination of both physicochemical analysis and biological assays. Implementation of a stability program is required for formal stability studies, and the studies should be executed according to a protocol that contains detailed information about types of tests, including specifications, testing intervals, and data and analysis.

A final container of vaccine contains the active ingredient(s) (i.e., antigen(s)) as well as additional components, such as stabilizers, adjuvants, or antimicrobial preservatives. They also may include residual materials from the manufacturing process.
Excipients and Other Additives
In addition to specific antigens, vaccines often include excipients and other additives that are intentionally added to the vaccine by the manufacturer for a specific purpose. These include adjuvants, antimicrobial preservatives, and stabilizers. Vaccines also contain manufacturing residuals, which are trace amounts of various components used during manufacturing. Thus, the combinations of these components comprise and define the complete vaccine product. Manufacturers must adhere to regulations governing permissible limits of such components, as indicated in the product's license.
Adjuvants— Adjuvants are agents incorporated into vaccine formulations to enhance and increase the immune responses generated by the vaccine antigens. Specifically, they can increase the amount of antibody produced, direct the immune response (Th1 or Th2), increase the duration of antibody presence (persistence), or produce a combination of these effects.
Aluminum compounds have long been the most widely used adjuvants worldwide. Two methods traditionally have been used for combining aluminum adjuvant to antigen to form aluminum-adsorbed vaccines. The first involves the addition of the antigen solution to preformed aluminum precipitate. The second involves the addition of an antigen to aluminum in solution and the addition of a compound that will coprecipitate the aluminum salt and the antigen in situ. Solutions of aluminum potassium sulfate, known as alum or aluminum chloride, have been used together with phosphate salts as precipitating agents. A number of aluminum adjuvant formulations are used in vaccines.
Tests for aluminum are based on metal detection tests described in the general test chapter Aluminum 206. Regulations limit the amount of aluminum permitted in a dose of vaccine. The Code of Federal Regulations [21 CFR 610.15(a), Ingredients, preservatives, diluents, adjuvants] states that “the amount of aluminum in the recommended individual dose of a biological product shall not exceed:
  1. 0.85 milligrams if determined by assay;
  2. 1.14 milligrams if determined by calculation on the basis of the amount of aluminum compound added; or
  3. 1.25 milligrams determined by assay provided that the data demonstrating that the amount of aluminum used is safe and necessary to produce the intended effect and are submitted to and approved by the Director, CBER [Center for Biologics Evaluation and Research at FDA].”
The third criterion above aligns U.S. regulations with World Health Organization guidance for aluminum content in a single human dose of a vaccine product.
Note that adjuvants are not licensed by themselves; they do not constitute a product. Rather, a vaccine consisting of specific antigen(s) and an adjuvant are licensed together as a drug product.
Antimicrobial Preservatives— In the case of multiple-dose containers, antimicrobial preservatives are added to inhibit the growth of microorganisms that may be introduced from repeated puncture of multidose vials. With certain exceptions, a preservative is required to be present in vaccines marketed in multidose containers [21 CFR 610.15(a)]. Exceptions include yellow-fever vaccine; measles, mumps, and rubella (MMR); and dried vaccines when the accompanying diluent contains a preservative.
The microbial preservatives currently used in vaccines are thimerosal, 2-phenoxyethanol, benzethonium chloride, and phenol. These agents must pass the appropriate antimicrobial effectiveness test, as described in Antimicrobial Effectiveness Testing 51. Antimicrobial test challenges should be conducted as part of the normal formal stability program, including at expiration date. Various tests for preservatives can be found in Antimicrobial Agents—Content 341.
Stabilizers— The primary purpose of stabilizers is to protect certain vaccines from adverse conditions such as heat or to serve as a cryopreservative during the lyophilization process, usually the freezing step. The particular materials chosen for this purpose include sugars (e.g., sucrose or lactose), amino acids (e.g., glycine or glutamic acid [monosodium salt]), glycerol, and proteins (e.g., human serum albumin [HSA] or gelatin). Materials should be customized to a specific vaccine formulation and selected with patient safety in mind.
When a protein is chosen as a stabilizer, two main safety concerns arise. One stems from the source of the protein: animal or human origin raises the possibility of the presence of an adventitious agent. The second concern is the possibility of an allergic reaction in persons sensitized to that protein. This should be evaluated as part of the clinical program during vaccine development. At present two proteins are used as stabilizers for vaccines: HSA and gelatin. FDA requires that any serum-derived albumin used in manufacturing be U.S.-licensed HSA. FDA guidance further recommends that a statement indicating the source and related risks appear in the “Warnings” section of the labeling for HSA-containing products.
Gelatin or processed gelatin also is used as a vaccine stabilizer. The gelatin source may be either bovine or porcine. Although the conditions of manufacturing gelatin are harsh (i.e., the product is subjected to extremes of heat and pH), there remains a concern with bovine sources about the presence of the transmissible spongiform encephalopathy (TSE) agent, because this agent is known to resist such conditions. Therefore, if gelatin added to a vaccine or used in manufacturing is from a bovine source, the material should have the appropriate documentation certifying that it comes from a country or region that is in compliance with TSE guidance for industry.
Manufacturing Residuals— Vaccines may contain residual amounts of any of the materials used in the manufacturing process. These materials are termed manufacturing residuals. As a general principle, it is not possible to remove a particular substance completely, nor is it possible to conclusively demonstrate that a particular substance has been completely removed. Therefore the goal is to reduce these substances to an undetectable level, using a sensitive and validated analytical methodology. Some products are tested for pyrogenic substances as a manufacturing residual (see Pyrogen Test 151); and, if the product is freeze-dried, it should be tested for residual moisture (see Loss on Drying 731). Residual levels of manufacturing materials, including, if applicable, inactivating agents, should be justified. The release specifications of these components are required as part of the approved license.
Cell-Derived Residuals— Live attenuated bacterial vaccines are not usually subject to a high degree of postexpansion purification. But killed bacterial component vaccines typically undergo significant purification to reduce cell-derived residuals. Common cellular components to be reduced are proteins, nucleic acids, and polysaccharides. Assays for these components are routinely conducted, if appropriate, to ensure purity. A common residual in bacterial vaccines made from Gram-negative bacteria is lipopolysaccharide (LPS), commonly known as endotoxin. Endotoxin testing is performed during the manufacturing process for any Gram-negative bacterial vaccine. In the case of Gram-positive bacterial vaccines, the endotoxin testing should be conducted to ensure that no contaminants from Gram-negative bacterial growth are present. Also, there must be a release specification for this residual. Two tests are currently used to detect LPS in biological products, the Limulus amebocyte lysate (LAL) test (see Bacterial Endotoxins Test 85) and the rabbit pyrogen test (see Pyrogen Test 151). The Limulus lysate that is used to test for bacterial endotoxin in FDA-regulated products is itself a U.S.-licensed product. The rabbit pyrogenicity test requires the use of animals and is more difficult to perform; therefore, it is not employed to the extent that the LAL test is used.
Viral vaccine manufacturing requires cell substrates to produce the viruses, which are then taken through purification processes. Generally, killed viral vaccines are more highly purified than are live attenuated ones. Depending on the method used to manufacture the vaccine, manufacturers work with FDA to develop prudent specifications for the final vaccine. Animal-derived host cells have been used extensively in vaccine manufacturing, particularly viral vaccines. For example, influenza and yellow fever vaccines are produced, respectively, in egg allantoic fluid and chicken embryos. Mumps, measles, and some rabies vaccines are produced in chick embryo cells. The labels of these products must state that residual chicken proteins may be present in the final vaccine, and the label may indicate how much is present. Further, the label also urges practitioner caution when vaccinating a person with known hypersensitivity to eggs.
Two U.S.-licensed hepatitis B vaccines are based on recombinant DNA-derived proteins expressed in yeast cultures. In both cases, the labels notify health care professionals that yeast protein may be present in the vaccine and recommend that suitable precautions should be exercised. In the case of live viral vaccines, considerations may be given to the reduction of cellular residual materials (e.g., host DNA, proteins).
Materials of Animal Origin— Some raw materials and reagents, such as gelatin, calf serum (see Bovine Serum 1024), or trypsin for vaccine manufacturing raise concerns regarding the potential presence of adventitious agents. Raw materials should be sourced from countries acceptable to FDA. Additionally, manufacturers should test these materials when possible to minimize the risks of contamination with adventitious agents. Reduction of serum components (e.g., BSA) should be considered in processing.
Antibiotic Residuals— Some antibiotics (but not penicillin) can be used in minimal amounts in the manufacturing process for viral vaccines, according to 21 CFR 610.15(c). Those that have been used include gentamicin, streptomycin, neomycin, and polymyxin B. There is no requirement for tests of residual levels of these antibiotics in the final vaccine. However, according to 21 CFR 610.61(m), the calculated amount expected to remain as a residual in the final vaccine, based on the amount added and the dilution factor in the manufacturing process, must be stated on the product label.
Inactivating Chemical Agents— Several chemical agents have been used to inactivate bacteria and viruses or to detoxify toxins in vaccine production processes. Formaldehyde and -propiolactone are the most commonly used inactivating agents. Other less often used inactivating agents include glutaraldehyde and hydrogen peroxide. As a manufacturing residual, the inactivating agent should be removed from the final product as thoroughly as possible. The upper limit for formaldehyde is generally 0.02%, equivalent to 0.1 mg per 0.5-mL vaccine dose. The limit for -propiolactone should be below the limit of detection.

The stability of vaccine products depends on the nature of a vaccine antigen, the product formulation, and the control of vaccine storage prior to use.
Vaccine products are evaluated with programs that include real-time long-term storage under prescribed conditions. The use of extreme temperatures to potentially accelerate degradation may help manufacturers understand the stability of the product.
Vaccine products, like all pharmaceutical products, should be evaluated to define suitable conditions for storage (21 CFR 610.50 and 610.53). General principles of stability testing for biological products are described in Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products 1049. Typically these concerns are focused on the final vaccine product, but evaluations also are needed for bulk intermediates to justify the conditions under which they are held. In both cases manufacturers define in advance the conditions to which the product will be exposed (e.g., temperature, light, and humidity) and the time range during which the product will be exposed to those conditions. Stability studies should evaluate all storage conditions to which the product or intermediate is likely to be exposed during production, handling, shipping, and storage so that appropriate time limits can be placed on the exposure to those conditions.
The primary criteria for defining the storage conditions for these intermediates and the final products are generally focused on acceptable maintenance of potency; but, as discussed below, there often are other attributes that need to be considered.
Evaluation of the stability of vaccine products has three general purposes. First, the products are shown to maintain an acceptable analytical profile throughout manufacture and use to preserve safety and effectiveness. Second, stability studies across several product batches provide an effective way to characterize the inherent properties of the product. This in turn leads to the third use, demonstrating manufacturing consistency in the product.
Stability Protocols
The overall experimental plan for evaluating the stability profile of a given set of product or intermediate batches typically includes specific definition of the conditions under which the samples will be stored and why these conditions are relevant, the length of time the samples will be stored at each condition, when samples will be tested during this time course, and the analytical measurements at each time point. Additionally, these stability protocols include itemization of the analytical procedures to be used. For stability studies that occur early in product development, the studies may be conducted to confirm the suitability of the product formulation and/or storage conditions. Later in development, stability studies are typically conducted to provide data supporting product dating period or intermediate hold time, to provide more elaborate product characterization, and to evaluate manufacturing consistency. These latter studies define product end–expiry specifications that allow definitions of acceptable and unacceptable product. Unacceptable product is defined as product that is no longer acceptable for use in clinical studies or for commercial use (e.g., because of degradation or loss of potency). Stability studies should be conducted over a duration sufficient to determine the point of loss of acceptable potency or other relevant parameters.
Analytical Measurements
Manufacturers should consider the rigor of the analytical method(s) used to evaluate the stability of complex products and improve their understanding of the parameters that are critical to immunogenicity (including stability-indicator parameters). Selection of the stability-indicator parameters varies with each vaccine's unique characteristics.
The primary parameter that reflects stability for most vaccines is the potency assay (see Potency Tests in Lot Release Testing, below). This assay can take many forms, depending on individual vaccines (e.g., an infectivity assay for a live virus vaccine or a measure of the proportion of conjugated polysaccharide for a polysaccharide–protein conjugate vaccine). The potency assay is generally the key analytical result predicting whether a vaccine remains suitable for use and whether it will produce the expected clinical response. Other analytical measurements can provide important supplemental data, particularly those that have a clear link to the potency of the product. Examples include degradation profile, dissociation of a carrier protein from conjugated vaccines, and dissociation of an adjuvant from an antigen complex. Additionally, other common assays typically are performed as part of the stability study and may address physical or chemical changes in the product that may or may not affect its potency (e.g., general safety, degree of aggregation, pH, moisture, container, preservative, and enclosure).
Formal Evaluation of Stability Data and Product Expiry Dating
Vaccines must remain within potency specifications at the expiration date, provided that the product was stored under the normal conditions specified. Manufacturers should conduct stability studies to determine those storage conditions and that dating period to demonstrate that the product remains within the potency specifications. Manufacturers should conduct stability studies on a continuing basis. If a major manufacturing process changes, additional stability studies should be conducted to verify that there is no adverse impact on the stability profile. Under certain conditions such as process changes, accelerated stability studies could be conducted. An accelerated study involving temperatures both higher and lower than routine can evaluate the impact of temperature excursions on products. A similar evaluation should be done for product intermediates to establish how long a given intermediate can be held under defined conditions before it is processed further or discarded.

There are no uniform systems for naming new vaccines. 21 CFR 299 describes the cooperation of the FDA and the U.S. Adopted Names Council (USAN) in naming drugs, including vaccines. USAN is a private organization sponsored by the American Medical Association, USP, and the American Pharmacists Association. Section 262 in Title 42 of the Public Health Service Act requires that each package of the biological product be plainly marked with the proper name (name designated in the license 21 CFR 600.3) of the biological product contained in the package.

Vaccine product labeling is regulated in compliance with 21 CFR 201 and 610. Requirements are set for container labeling and package labeling.
Container Label
Provisions are made for the following labels:
  • Full label;
  • Partial label; and
  • No label on the container itself when the containers cannot support a label that includes all required information and should be placed in a package that does include all required information.
The label should be affixed to the container in a manner that allows visual inspection of the contents for the full length or circumference of the container. If no package exists, the container bears all of the information required for the package label.
The full container label normally contains the following:
  • Proper name of the product;
  • Name, address, and license number of the manufacturer;
  • Lot number or other lot identification;
  • Expiration date;
  • Recommended individual dose, for multiple-dose containers;
  • The phrase Rx only for prescription biologicals; and
  • Any applicable cautionary statements.
Package Label
In addition to the information required on the container label, the package label should describe the following:
  • Any preservative used and its concentration, or the words no preservative if no preservative is used and its absence is a safety factor;
  • Number of containers, if more than one; or
  • Amount of product in the container, expressed as number of doses, volume, units of potency, weight, and equivalent volume (for dried product to be reconstituted); or
  • A combination of the above to provide an accurate description of the contents, as applicable;
  • Recommended storage temperature;
  • The words shake well, do not freeze, or the equivalent, as well as other instructions when indicated by the character of the product;
  • Recommended individual dose, for multiple-dose containers;
  • Recommended route of administration, or reference to such directions in an enclosed circular;
  • Presence of known sensitizing substances;
  • Type of antibiotics added during manufacture and the amount calculated to remain in the final product;
  • Inactive ingredients, when they constitute a safety factor or are referenced to an enclosed circular;
  • Adjuvant, if present;
  • Source of the product, when this may be a factor in safe administration;
  • Identity of each microorganism used in manufacture and, if applicable, the production medium and the method of inactivation or reference to an enclosed circular;
  • Minimum potency in terms of official standard of potency, or the words no U.S. standard of potency.
Prescribing Information
Detailed information about a vaccine appears in its prescribing information, commonly called the package insert. Increasingly, vaccines are distributed with patient package inserts written in lay language. Prescribing information (21 CFR 201.56 and 201.57) includes the following:
  • Highlights of prescribing information
  • Product names, other required information
  • Boxed warning
  • Recent major changes
    1. Indications and usage
    2. Dosage and administration
    3. Dosage forms and strengths
    4. Contraindications
    5. Warnings and precautions
    6. Adverse reactions
    7. Drug interactions
    8. Use in specific populations (e.g., pregnancy, nursing mothers, pediatric, geriatric)
    9. Drug abuse and dependence
    10. Overdosage
    11. Description
    12. Clinical pharmacology
    13. Nonclinical toxicology
    14. Clinical studies
    15. References
    16. How supplied/storage and handling
    17. Patient counseling information

General Principles
Manufacturers perform all appropriate tests for the licensed specifications for the product, according to 21 CFR 610.1 and 610.2. Samples of each licensed lot and protocols containing the manufacturers' test results are submitted to FDA. After FDA evaluates the protocol to ensure that the product specifications are met, and after satisfactory confirmatory testing, FDA approves the release of the lot if all tests meet the standards of safety, purity, and potency established for the particular vaccine product. After approval is granted, the manufacturer distributes and markets the product.
Guidelines are available regarding alternatives to lot release and a surveillance system. All of these variations are subject to the regulations in 21 CFR 610.2 that allow FDA to require that samples of any lot of licensed product (e.g., vaccine), together with the protocols showing results of applicable tests, be sent to FDA.
Common Tests
The tests common to all lots of all products include tests for potency, general safety, sterility, purity, identity, and constituent materials. The manufacturer completes these tests for conformity with standards applicable to each product. The results of all tests are considered, except when a test has been invalidated as a result of causes unrelated to the product (21 CFR 610.1).
Potency Tests (Vaccine-Specific)— The basic definition and requirements for vaccine potency and potency assays are provided in 21 CFR 600.3 and 610.10. A vaccine potency assay should indicate the therapeutic activity of the drug product as indicated by appropriate laboratory tests or by adequately developed and controlled clinical data. Potency may be expressed in terms of units by reference to a standard. Product potency tests vary with vaccine product types (e.g., viral, bacterial, live attenuated, inactivated, or polysaccharide). As a result, potency assays for vaccines span a variety of approaches to the expression of potency. In vitro potency tests for live virus may include plaque formation assays, endpoint dilution assays (e.g., the tissue culture infective dose [TCID50], virus neutralization assays, or quantitative polymerase chain reaction [PCR] assays). Quantitative colony formation assays are used for live attenuated bacterial vaccines. Animal challenge tests for immunogenicity assays of potency, such as those for diphtheria and tetanus (U.S. Department of Health, Education, and Welfare, 1953; see Appendix 2), or rabies and anthrax show in vivo response. Antigenicity assays use enzyme-linked immunosorbent assays (ELISA), e.g., with hepatitis A or rate nephelometry and rocket immunoelectrophoresis (e.g., with pneumococcal polysaccharides). The potency tests for bacterial vaccines, such as the meningococcal polysaccharides, pneumococcal polysaccharides, or Haemophilus b protein conjugate vaccines use chemical and physical chemical assays. In the case of pure polysaccharide vaccines, the concentration or quantity of the vaccine component (polysaccharide) and its quality (e.g., size) have been shown to be indicative of human immune response.
Assay precision and reproducibility vary with the different methodologies that are used in potency assays, ranging from the high accuracy and precision of chemical tests at one end of the spectrum to bioassays at the other end. The general test chapter Design and Analysis of Biological Assays 111 provides guidance for bioassays and applies to vaccine potency assays. Other tests should be validated as described in the general information chapter Validation of Compendial Procedures 1225.
Release Tests— Official release of vaccines by the vaccine regulatory authority may be based on either the bulk or the final container. It is highly desirable to perform potency tests on the final container. However, under certain circumstances this may not be practical or even possible: thus, a case-by-case approach would be required. The choice of whether to test the bulk or the final container derives from a number of considerations, such as the quantity of vaccine available for tests at the different manufacturing stages. For certain vaccines, both bulk and final container receive official release. The potency test is generally required for the final container. If it is not feasible to perform the potency test on the final drug product, the test is performed on the bulk material.
General Safety— For biological products that are intended for administration to humans, manufacturers perform a general safety test in order to detect any extraneous toxic contaminants. Procedures and exceptions are specified in 21 CFR 610.11.
Sterility— A sterility test of each lot of each product is conducted according to procedures described in Sterility Tests 71 and 21 CFR 610.12 for both bulk and final container material.
Bacterial Endotoxins— Each lot of final containers of a vaccine intended for use by injection is tested for bacterial endotoxins, as indicated in Bacterial Endotoxins Test 85.
Purity— Vaccines need to be free of extraneous material. Approved vaccine license applications indicate extraneous materials that are unavoidable in the manufacturing process for a specific product. The application may indicate test results and allowable limits for such materials, according to procedures described in 21 CFR 610.13.
Residual Moisture— Each lot of dried product is tested for residual moisture [see 21 CFR 610.13 (a), Loss on Drying 731, and FDA’s Guideline for the Determination of Residual Moisture in Dried Biological Products (see Appendix 2)].
Pyrogens— Each lot of final containers of a vaccine intended for use by injection is tested for pyrogenic substances, as indicated in Pyrogen Test 151 and 21 CFR 610.13 (b).
Identity— The contents of a final container of each filling of each lot are tested for identity after labeling is completed. Identity is established by physical or chemical characteristics of the vaccine, inspection by macroscopic or microscopic methods, specific cultural tests, or in vivo or in vitro immunological tests. In large part, identity tests are performed to distinguish the subject vaccine from other materials manufactured at the same site (21 CFR 610.14).
Constituent Materials— Ingredients, preservatives, diluents, adjuvants, extraneous protein, cell culture-produced vaccines, and antibiotics are tested according to 21 CFR 610.15.
Permissible Combinations
Formulations that combine several vaccines must be licensed as combinations (21 CFR 610.17). The potency of each vaccine in the combination is individually tested and must meet the specifications in the context of the final combined product; other appropriate quality tests apply as well. For vaccines that are physically combined in clinical locations just before administration to a patient, prescribing information should describe specific procedures to follow in those settings.
In general, quality control systems for vaccine manufacture are identical to those routinely employed for production of other pharmaceuticals. These include raw material testing and release, manufacturing, process-control documentation, and aseptic processing. Manufacturers formally assign responsibility to designated staff for maintaining the continued safety, purity, and potency of the product and for ensuring compliance with applicable product and establishment standards, along with compliance with current GMPs. Analysts use reference standards and validated methods to determine active ingredients, residuals, and impurities. Manufacturers determine product safety in a variety of ways that may include the use of experimental animals, procedures to demonstrate product sterility, and tests to ensure product potency. The complexity of the quality control systems for vaccines lies in the variety of methods used to produce and control production. Lot release testing proceeds according to 21 CFR 610.2 and involves evaluating lots for safety, purity, and potency before release. Manufacturers follow FDA and applicable international standards for testing and validation. The basic considerations for validation are included in Validation of Compendial Procedures 1225, in addition to guidance documents issued by FDA and the International Conference on Harmonization (ICH) (see Appendix 2).
Alternative Tests
Modification of test methods or manufacturing processes as licensed may be permitted if the regulatory authority can be assured that the modifications cause no reduction in safety, purity, potency, and effectiveness of the biological product. It may be necessary for the manufacturer to file the proposed changes prior to implementation (21 CFR 601.12 and 21 CFR 610.9).

  • Bacterial, live attenuated (e.g., Salmonella typhi)
  • Bacterial, polysaccharide (e.g., meningococcal, pneumococcal)
  • Bacterial, polysaccharide-protein conjugate (e.g., meningococcal, pneumococcal)
  • Bacterial, toxoid (e.g., diphtheria, tetanus)
  • Bacterial, extracts (e.g., pertussis, anthrax)
  • Viral, live attenuated (e.g., influenza, measles, mumps, rubella)
  • Viral, whole inactivated (e.g., rabies)
  • Viral, subunit (e.g., influenza, hepatitis B, human papillomavirus)

  • 21 CFR 201.
  • 21 CFR 299.
  • 21 CFR 600.
  • 21 CFR 610.
  • Section 262 in Title 42 of the Public Health Service Act
  • Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA). Guidance for Industry—Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products (January 2002). http://www.fda.gov/cber/gdlns/cjdvcjd.pdf
  • Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA). Guideline for the Determination of Residual Moisture in Dried Biological Products (January 1990). http://www.fda.gov/cber/gdlns/moisture.pdf
  • Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA). Guidance on Alternatives to Lot Release for Licensed Biological Products. Federal Register 1993;58(137): 38771–38773. http://www.fda.gov/cber/gdlns/altrntvlot071493.pdf
  • Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA). Guidance For Industry—Characterization and Qualification of Cell Substrates and Other Biological Starting Materials Used in the Production of Viral Vaccines for the Prevention and Treatment of Infectious Diseases (September 2006). http://www.fda.gov/cber/gdlns/vaccsubstrates.pdf
  • FDA periodically issues or updates Guidance for Industry and posts these documents at http://www.fda.gov/cber/guidelines.htm
  • Department of Health, Education, and Welfare (now the National Institutes of Health). Minimum Requirements for Immune Serum Globulin (Human). 3rd rev. Bethesda, MD: Department of Health, Education, and Welfare, 1953.
  • International Conference on Harmonization (ICH). Q2(R1). Validation of Analytical Procedures: Text and Methodology. Geneva, Switzerland: ICH, 2005. http://www.ich.org/LOB/media/MEDIA417.pdf

  1. Acceptance criteria—The product specifications and acceptance or rejection criteria, with an associated sampling plan, necessary for making a decision to accept or reject a lot or batch (or any other convenient subgroups of manufactured units).
  2. Active ingredient—Any component intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man or other animals. The term includes those components that may undergo chemical change in the manufacture of the drug product and may be present in the drug product in a modified form intended to furnish the specified activity or effect.
  3. Adventitious agent—A microorganism (e.g., bacteria, fungi, mycoplasma, spiroplasma, mycobacteria, rickettsia, viruses, protozoa, parasites, TSE agent) that is inadvertently introduced into the production of a biological product.
  4. Batch—A specific quantity of a drug or other material intended to have uniform character and quality, within specified limits, and produced according to a single manufacturing order during the same cycle of manufacture.
  5. Biological product—Any virus, therapeutic serum, toxin, antitoxin, or analogous product applicable to the prevention, treatment or cure of diseases or injuries of man.
  6. Cell bank—Vials of cells of uniform composition (not necessarily clonal) derived from a single tissue or cell, aliquoted into appropriate storage containers, and stored under appropriate conditions.
  7. Cell line—Cells that have been propagated in culture since establishment of a primary culture and have survived through crisis and senescence. Such surviving cells are immortal and will not senesce. Diploid cell strains have been established from primary cultures and expanded into cell banks, but have not passed through crisis and are not immortal.
  8. Characterization—Determination of the properties of a substance.
  9. Component—Any ingredient intended for use in the manufacture of a drug product, including those that may not appear in such drug product.
  10. Container (also final container)—The immediate unit, bottle, vial, ampule, tube, or other receptacle containing the product as distributed for sale, barter, or exchange.
  11. Control—Having responsibility for maintaining the continued safety, purity, and potency of the product and for compliance with applicable product and establishment standards, and for compliance with current good manufacturing practices.
  12. Control cells—Cells that are split off from the production culture and maintained in parallel under the same conditions and using the same reagents (e.g., culture medium) to perform quality control tests on cells that have not been exposed to the vaccine virus (which may interfere with some tests).
  13. Dating period—The period beyond which the product cannot be expected beyond reasonable doubt to yield its specific results.
  14. Diploid—Having the expected number of chromosomes for a species (i.e., two of each autosomal chromosome and two sex chromosomes).
  15. Drug product—A finished dosage form (e.g., solution, suspension) that contains an active drug ingredient generally in association with inactive ingredients.
  16. End-of-production cells—Cells harvested at the end of a production run or cells cultured from the master cell bank or working cell bank to a passage level or population doubling level comparable to or beyond the highest level reached in production.
  17. End-of-production passage level—The maximal passage level achieved during manufacturing at final vaccine harvest. Cells may be evaluated at this level or beyond.
  18. Endogenous virus—A virus whose genome is present in an integrated form in a cell substrate by heredity. Endogenous viral sequences may or may not encode for an intact or infectious virus.
  19. Expiration date—The calendar month and year, and where applicable, the day and hour, that the dating period ends.
  20. Filling—A group of final containers identical in all respects, which have been filled with the same product from the same bulk lot without any change that will affect the integrity of the filling assembly.
  21. Final bulk—The stage of vaccine production directly prior to filling of individual vials.
  22. Free of and freedom from—For a substance to be considered free of a contaminant, an assay must demonstrate that a defined quantity of the substance is negative for that contaminant to a defined level of sensitivity. The level of assay sensitivity is defined by the choice of assay and can be determined experimentally using standardized reagents. Alternatively, a validated process that is known to remove a contaminant to a defined level may be used to demonstrate freedom from that contaminant.
  23. Harvest—Collection of material at the end of vaccine virus propagation in cell culture, from which vaccine will be prepared. This material may be the culture supernatant, the cells themselves (often in disrupted form), or some combination thereof.
  24. Inactive ingredient—Any component other than an active ingredient.
  25. In-process material—Any material fabricated, compounded, blended, or derived by chemical reaction that is produced for, and used in, the preparation of the drug product.
  26. Intermediates—Unformulated active ingredients that are processed before final formulation and can be stored for long periods of time before further processing.
  27. Label—Any written, printed, or graphic matter on the container or package or any such matter clearly visible through the immediate carton, receptacle, or wrapper.
  28. Latent virus—A virus that is present in a cell, without evidence of active replication, but with the potential to reactivate, is considered to be microbiologically latent.
  29. Lot—A batch, or a specific identified portion of a batch, having uniform character and quality within specified limits; or, in the case of a drug product produced by continuous process, it is a specific identified amount produced in a unit of time or quantity in a manner that assures its having uniform character and quality within specified limits.
  30. Lot number, control number, or batch number—Any distinctive combination of letters, numbers, or symbols, or any combination of them, from which the complete history of the manufacture, processing, packing, holding, and distribution of a batch or lot of drug product or other material can be determined.
  31. Manufacture—All steps in the propagation or manufacture and preparation of products. Includes, but is not limited to, filling, testing, labeling, packaging, quality control, and storage by the manufacturer.
  32. Manufacturer—Any legal person or entity engaged in the manufacture of a product subject to license under the Public Health Service (PHS) Act. Manufacturer also includes any legal person or entity who is an applicant for a license where the applicant assumes responsibility for compliance with the applicable product and establishment standards.
  33. Master cell bank—A bank of a cell substrate from which all subsequent cell banks used for vaccine production will be derived. The master cell bank represents a characterized collection of cells derived from a single tissue or cell.
  34. Master virus seed—A viral seed of a selected vaccine virus from which all future vaccine production will be derived, either directly, or via working virus seeds.
  35. Oncogenicity—The property of certain biological agents (e.g., viruses) or materials (e.g., nucleic acids) that are capable of immortalizing cells and endowing them with the capacity to form tumors. Oncogenicity is distinct from tumorigenicity.
  36. Package—The immediate carton, receptacle, or wrapper, including all labeling matter therein and thereon, and the contents of the one or more enclosed containers. If no package is used, the container shall be deemed to be the package.
  37. Passage level—The number of times, since establishment from a primary cell culture, a culture has been split or reseeded.
  38. Population doubling level—The number of times, since establishment from a primary cell culture, a culture has doubled in number of cells.
  39. Potency—The therapeutic activity of the drug product as indicated by appropriate laboratory tests or by adequately developed and controlled clinical data. Potency may be expressed in terms of units by reference to a standard.
  40. Primary cells—Cells placed into culture immediately after an embryo, tissue, or organ is removed from an animal or human and homogenized, minced, or otherwise separated into a suspension of cells. Primary cells may be maintained in medium, but are not passaged (split).
  41. Process—A manufacturing step that is performed on the product itself which may affect its safety, purity, or potency, in contrast to such manufacturing steps which do not affect intrinsically the safety, purity, or potency of the product.
  42. Proper name—The name, designated in the license, to be used on each package of the product.
  43. Purity—Relative freedom from extraneous matter in the finished product, whether or not harmful to the recipient or deleterious to the product. Purity includes but is not limited to relative freedom from residual moisture or other volatile substances and pyrogenic substances.
  44. Qualification—Determination of the suitability of a material for manufacturing based on its characterization.
  45. Safety—The relative freedom from harmful effect to persons affected, directly or indirectly, by a product when prudently administered, taking into consideration the character of the product in relation to the condition of the recipient at the time.
  46. Specification—The quality standard (i.e., tests, analytical procedures, acceptance criteria) provided in an approved application to confirm the quality of products, intermediates, raw materials, reagents, components, in-process materials, container–closure systems, and other materials used in the production of a product.
  47. Standards—Specifications and procedures applicable to an establishment or to the manufacture or release of products, which are prescribed in this subchapter or established in the biologics license application and designed to ensure the continued safety, purity, and potency of such products.
  48. Sterility—Freedom from viable contaminating microorganisms, as determined by tests prescribed by the FDA.
  49. Tumorigenic—A property of certain cell types to form tumors when inoculated into animals (generally a syngeneic, an immunosuppressed allogeneic, or an immunosuppressed xenogeneic host). These tumors may be at the injection site or a different site and may also metastasize to other sites.
  50. Tumorigenicity—The process by which immortalized cells form tumors when inoculated into animals. Tumorigenicity is distinct from oncogenicity.
  51. Unacceptable product—Product that is no longer acceptable for use in clinical studies or for commercial use (e.g., because of degradation or loss of potency).
  52. Validation—The performance characteristics of an analytical procedure, based on the demonstration that the procedure is suitable for its intended purpose or use. Validation of a process is the determination of the extent to which a process meets the requirements for the various performance characteristics and the demonstration that the process uniformly performs to defined characteristics. Validation is generally performed in accordance with Validation of Compendial Procedures 1225 and the relevant ICH guidelines.
  53. Viral clearance—The combination of the physical removal of viral particles and the reduction of viral infectivity through inactivation.
  54. Virus seed or viral seed—A live viral preparation of uniform composition (not necessarily clonal) derived from a single culture process, aliquoted into appropriate storage containers, and stored under appropriate conditions.
  55. Working cell bank—A cell bank derived by propagation of cells from the master cell bank under defined conditions and used to initiate production cell cultures on a lot-by-lot basis.
  56. Working virus seed—A viral seed derived by propagation of virus from the master virus seed under defined conditions and used to initiate production cell cultures lot-by-lot.
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
General Chapter Ritu Agarwal, Ph.D.
Scientific Liaison
(GCBA2010) General Chapters - Biological Analysis
USP35–NF30 Page 907
Pharmacopeial Forum: Volume No. 35(4) Page 960